He remains cautiously optimistic, nevertheless, because the “base line is that you do see a discount in cancer incidence With all the GLP-one agonists,” he claims, and it’s possible that reduction will be even larger Should the scientists had only focused on patients with obesity or overweight. The needle go over will lock in the event the p